Grapefruit–drug interactions

The primary mechanism involves the irreversible inhibition of intestinal CYP3A4 by furanocoumarins, particularly bergamottin and 6',7'-dihydroxybergamottin, present in grapefruit juice.¹ This inhibition occurs in the small intestine, not the liver, and leads to increased oral bioavailability of drugs that undergo extensive first-pass metabolism by this enzyme. The effect can last for up to 24 hours after consumption, meaning that even a single glass of juice can significantly elevate drug levels if taken concurrently. Unlike competitive inhibitors, the inactivation is mechanism-based, requiring new enzyme synthesis for recovery, which explains the prolonged duration of the interaction.

Clinically significant interactions occur with a wide range of drugs, including statins (e.g., simvastatin, atorvastatin), calcium channel blockers (e.g., felodipine, nifedipine), immunosuppressants (e.g., cyclosporine, tacrolimus), and certain psychotropics (e.g., buspirone, diazepam).² The consequences can be severe, ranging from rhabdomyolysis with statins to nephrotoxicity with immunosuppressants.³ The interaction is dose-dependent; consuming larger amounts of juice or consuming it closer to drug administration increases the risk. However, not all drugs in a class are affected equally; for example, pravastatin and rosuvastatin are minimally affected because they are not primarily metabolized by CYP3A4.² Patients are advised to avoid grapefruit juice entirely while taking susceptible medications, as even small amounts can be problematic.

The interaction was first discovered serendipitously in 1989 by a research group at the University of Western Ontario, led by David Bailey, who observed an unexpected increase in felodipine levels when the drug was administered with grapefruit juice in a study designed to mask its taste.⁴ Subsequent research identified the furanocoumarins as the active inhibitors and clarified the mechanism.¹ Since then, the list of interacting drugs has grown, and regulatory agencies such as the FDA have mandated labeling for many products. The discovery highlighted the importance of food–drug interactions and led to broader investigations into other fruit juices, such as pomelo and Seville orange, which contain similar compounds.

Beyond CYP3A4, grapefruit juice also inhibits the drug transporter P-glycoprotein (P-gp) and organic anion-transporting polypeptides (OATPs), which can either increase or decrease drug absorption depending on the substrate. For instance, fexofenadine levels are reduced because OATP inhibition decreases its uptake, while cyclosporine levels increase due to CYP3A4 and P-gp inhibition.⁵ The interaction is not limited to juice; the whole fruit, including segments and peel, contains the active compounds. Additionally, the effect varies with grapefruit variety and processing; white grapefruit and freshly squeezed juice have higher furanocoumarin content than some commercial juices. Some drugs, such as dihydropyridine calcium channel blockers, are particularly sensitive, and even a single glass can produce a several-fold increase in plasma concentrations.

CYP3A4

A cytochrome P450 enzyme responsible for metabolizing many drugs; inhibited by grapefruit furanocoumarins.

Furanocoumarins

Naturally occurring organic compounds in grapefruit that irreversibly inhibit CYP3A4.

First-pass metabolism

The initial metabolism of a drug in the intestine and liver before reaching systemic circulation.

P-glycoprotein

An efflux transporter that pumps drugs out of cells; also inhibited by grapefruit juice.